CRISPR Therapeutics
CRSP
CRSP
444 hedge funds and large institutions have $3.21B invested in CRISPR Therapeutics in 2024 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 157 increasing their positions, 126 reducing their positions, and 75 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
444
Holders Change
-36
Holders Change %
-7.5%
% of All Funds
6.46%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.07%
New
49
Increased
157
Reduced
126
Closed
75
Calls
$127M
Puts
$119M
Net Calls
+$7.93M
Net Calls Change
-$36.1M
Top Buyers
1 |
State Street
Boston,
Massachusetts
|
$129M |
2 |
UBS AM
Chicago,
Illinois
|
$37.5M |
3 |
FCM
Farallon Capital Management
San Francisco,
California
|
$28.6M |
4 |
BlackRock
New York
|
$150M |
5 |
TCM
Tang Capital Management
San Diego,
California
|
$17.1M |